Compare DexCom, Inc. (DXCM) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Teladoc Health Inc — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Teladoc Health Inc trades at $9.65 (market cap $1.75B). The key difference: DexCom, Inc. is far larger — about 16× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | TDOC | |
|---|---|---|
Market Cap | $28.06B | $1.75B |
Sector | Health | Health |
52-Week High | $89.53 | $9.72 |
52-Week Low | $54.84 | $4.47 |
Enterprise Value | $27.03B | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
TDOC trades at $9.27, down 3.94% on the day, with a bullish technical signal from moving averages. The company reported revenue of $2.53B in 2025 but posted a net loss of $200.32M. Recent news highlights the Walmart partnership expansion and upcoming Q2 2026 earnings. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.
The outlook remains cautious due to persistent losses despite revenue stability. Investment opportunity exists if cost controls and partnerships drive profitability. Key risks include competitive pressures, weak BetterHelp segment, and negative cash flow trends. The stock faces headwinds until sustainable earnings improvement is demonstrated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
